Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenxoneWAR:GX1 -0.35%66 Market Cap is zł18.77 Mil as of Jul. 22, 2026. GuruFocus rates WAR:GX1 with a GF Score™ of 66/100 and a GF Value™ of zł6.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Genxone ranks worse than 90.93% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genxone's share price for the quarter that ended in Mar. 2026 was zł6.86. Genxone's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 3.31 Mil. Therefore, Genxone's market cap for the quarter that ended in Mar. 2026 was zł22.67 Mil.
Genxone's quarterly market cap
declined
from Sep. 2025 (zł18.38 Mil) to Dec. 2025 (zł13.19 Mil) but then
increased
from Dec. 2025 (zł13.19 Mil) to Mar. 2026 (zł22.67 Mil).
Genxone's annual market cap
increased
from Dec. 2023 (zł17.74 Mil) to Dec. 2024 (zł20.49 Mil) but then
declined
from Dec. 2024 (zł20.49 Mil) to Dec. 2025 (zł13.19 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genxone's Enterprise Value for Today is zł15.71 Mil.
Genxone (WAR:GX1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genxone Market Cap Related Terms
Genxone Market Cap Historical Data
* Premium members only.
The historical data trend for Genxone's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GX1 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Genxone's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genxone Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genxone's Market Cap distribution charts can be found below:
* The bar in red indicates where Genxone's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genxone's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genxone (WAR:GX1) has a Market Cap of zł18.77 Mil as of Jul. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genxone and its competitors. According to the industry distribution chart, Genxone ranks #1294 out of 1423 companies in the Biotechnology industry, placing it in the top 90.9%.
Is Genxone's Market Cap too high?
Genxone's current Market Cap is zł18.77 Mil. Based on the distribution chart, Genxone ranks #1294 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genxone has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genxone ranks #1294 out of 1423 companies for Market Cap. This places Genxone in the lower half of its industry. The industry median Market Cap is 113.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.52, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genxone and its competitors. For the Biotechnology industry, the median Market Cap is 113.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genxone's current Market Cap is zł18.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.51, compared to a current price of zł5.68 — trading 12.7% below its estimated fair value. The current Market Cap is zł18.77 Mil. Genxone's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Genxone (WAR:GX1), the current Market Cap is zł18.77 Mil as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genxone (WAR:GX1) Overvalued in 2026?
Based on GuruFocus' analysis, Genxone stock appears to be undervalued.
The current stock price of zł5.68 is trading 12.7% below its estimated GF Value™ of zł6.51.
GuruFocus considers Genxone to be Modestly Undervalued.
Key valuation signals for WAR:GX1:
Market Cap: zł18.77 Mil
GF Value™: zł6.51 vs. price of zł5.68 (12.7% below fair value)
No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
66GF Score
Get the complete analysis for WAR:GX1
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GX1 has been successfully added to your 
